Animal models of hypertrophic cardiomyopathy

Current Opinion in Cardiology

Volumn 15, Issue 3, 2000, Pages 189-196

  Maass, Alexander ^a   Leinwand, Leslie A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN HEAVY CHAIN; TROPOMYOSIN; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; GENE MUTATION; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; MYOFILAMENT; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RABBIT; REVIEW; SARCOMERE; THIN FILAMENT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARDIOMYOPATHY, HYPERTROPHIC; CRICETINAE; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MICE; MUTATION; MYOSIN HEAVY CHAINS; PHENOTYPE; RABBITS; RATS; SARCOMERES; TROPOMYOSIN; TROPONIN T;

EID: 0034042102     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200005000-00012     Document Type: Review

References (67)

1. 1 Wigle ED, Rakowski H, Kimball BP, Williams WG: Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995, 92:1680-1692.
2. 2 Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997, 350:127-133.
3. 3 Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation 1995, 92:785-789.
4. 4 Elliott PM, D'Cruz L, McKenna WJ: Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiac troponin T gene. Lancet 1999, 341:1855-1856.
5. 5 Nimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, et al.: Mutations in the gene for cardiac myosin binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
6. 6 Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO: Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
7. 7 Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG: A molecular basis for familial hypertrophic cardiomyopathy: a beta-cardiac myosin heavy chain gene missense mutation. Cell 1990, 62:999-1006.
8. 8 Mogensen J, Klausen IC, Pedersen AK, Egeblad H, Bross P, Kruse TA, et al.: α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:R39-R43.
9. 9 Bonne G, Carrier L, Richard P, Hainque B, Schwartz K: Familial hypertrophic cardiomyopathy - from mutations to functional defects. Circ Res 1998, 83:580-593.
10. 10 Klues HG, Schiffers A, Maron BJ: Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-1708.
11. 11 Fananapazir L, Epstein ND: Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain mutations. Circulation 1994, 89:22-32.
12. 12 Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Richard P, et al.: Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997, 8:107-114.
13. 13 Maron BJ, Casey SA, Gohmann TE, Aeppli DM: Impact of gender on the clinical and morphologic expression of hypertrophic cardiomyopathy. Circulation 1999, 100:1-212.
14. 14 James JF, Hewett TE, Robbins J: Cardiac physiology in transgenic mice. Circ Res 1998, 82:407-415.
15. 15 Cuda G, Fananapazir L, Epstein ND, Sellers JR: The in vitro activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 1997, 18:275-283.
16. 16 Lankford EB, Epstein ND, Fananapazir L, Sweeney HL: Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995, 95:1409-1414.
17. 17 Szczesna D, Zhang R, Zhao J, Jones M, Guzman G, Potter JD: Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J Biol Chem 2000, 275:624-630.
18. 18 Morimoto S, Yanaga F, Minakami R, Ohtsuki I: Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 1998, 275(Cell Physiol44):C200-C207.
19. 19 Sweeney HL, Feng HS, Yang Z, Watkins H: Functional analysis of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci USA 1998, 95:14406-14410.
20. 20 Rust EM, Albayya FP, Metzger JM: Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest 1999, 103:1459-1467.
21. 21 Marian AJ, Zhao G, Seta Y, Roberts R, Yu Q-Y: Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiornyopathy, impairs adult cardiac myocyte contractility. Circ Res 1997, 81:76-85.
22. 22 Nakaura H, Yanaga F, Ohtsuki I, Morimoto S: Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers. J Biochem 1998, 126:457-460.
23. 23 Tobacman LS, Lin D, Butters C, Landis C, Back N, Pavlov D, Homsher E: Functional consequences of troponin T mutations found in hypertrophic cardiomyopathy. J Biol Chem 1999, 274:28363-28370.
24. 24 Morimoto S, Nakaura H, Yanaga F, Ohtsuki I: Functional consequences of a carboxyl terminal missense mutation Arg278Cys in human cardiac troponin T. Biochem Biophys Res Comm 1999, 261:79-82.
25. 25 Nakaura H, Morimoto S, Yanaga F, Nakata M, Nishi H, Imaizumi T, Ohtsuki I: Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. Am J Physiol 1999, 277 (Cell Physiol 46):C225-C232.
26. 26 Michele DE, Albayya FP, Metzger JM: Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant α-tropomyosins in adult cardiac myocytes. Nat Med 1999, 5:1413-1417.
27. 27 Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, et al.: A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998, 82:106-115.
28. 28 Geisterfer-Lowrance AAT, Christe ME, Conner DA, Ingwall JS, Schoen FJ, Seidman CE, Seidman JG: A mouse model of familial hypertrophic cardiomyopathy. Science 1996, 272:731-734.
29. 29 Vikstrom KL, Factor SM, Leinwand LA: Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol Med 1996, 2:556-567.
30. 30 Fatkin D, Christe ME, Aristazabal O, McConnell BK, Srinivasan S, Schoen FJ, et al.: Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the α cardiac myosin heavy chain gene. J Clin Invest 1999, 103:147-153.
31. 31 Georgakopoulos D, Christe ME, Giewat M, Seidman CE, Seidman JG, Kass DA: The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med 1999, 5:327-330. In this study, contraction kinetics of hearts from 6-week-and 20-week-old α-MyHC-R403Q mice showed temporal evolution of changes similar to human disease.
32. 32 Gao WD, Perez NG, Seidman CE, Seidman JG, Marban E: Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest 1999, 103:661-666.
33. 33 Spindler M, Saupe KW, Christe ME, Sweeney HL, Seidman CE, Seidman JG, Ingwall JS: Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. J Clin Invest 1998, 101:1775-1783.
34. 34 Berul CI, Christe ME, Aronovitz MJ, Seidman CE, Seidman JG, Mendelsohn ME: Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 1997, 99:570-576.
35. 35 Bevilacqua LM, Maguire CT, Seidman JG, Seidman CE, Berul CI: QT dispersion in alpha-myosin heavy-chain familial hypertrophic cardiomyopathy mice. Pediatr Res 1999, 45:643-647.
36. 36 Vikstrom KL, Bohlmeyer T, Factor SM, Leinwand LA: Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 1998, 82:773-778.
37. 37 Marian AJ, Wu Y, Lim D-S, McCluggage M, Youker K, Yu Q, et al.: A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 1999, 104:1683-1692. The transgenic rabbit model with the β-MyHC-R403Q mutation described in this article is the first rabbit model of the disease. It showed the typical histologic features of FHC and premature death. Contrary to small rodents, rabbits show the same myosin isoform composition as humans and are therefore well suited for the investigation of myosin mutations.
38. 38 Welikson RE, Buck SH, Patel JR, Moss RL, Vikstrom KL, Factor SM, et al.: Cardiac myosin heavy chains lacking the light chain binding domain cause hypertrophic cardiomyopathy in mice. Am J Physiol 1999, 276 (Heart Circ Physiol 45):H2148-H2158. This mouse model with a deletion of the MLC binding domain in MyHC showed the typical FHC histopathology in addition to severe valvular pathology, being the first animal model with valve alterations.
39. 39 Jones WK, Grupp IL, Doetschmann T, Grupp G, Osinska H, Hewett TE, et al.: Ablation of the murine α myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest 1996, 98:1906-1917.
40. 40 Sanbe A, Fewell JG, Gulick J, Osinska H, Lorenz J, Hall DG, et al.: Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. J Biol Chem 1999, 274:21085-21094.
41. 41 Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, et al.: A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998, 101:2800-2811.
42. 42 Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, et al.: Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 1999, 104:469-481. Mice expressing high levels of their TnT as a missense mutation (R92Q) showed histopathologic features of FHC and induction of hypertrophic markers, but no LV hypertrophy, but rather smaller size of LV caused by smaller myocytes. Functional analyses of these hearts showed hypercontractility with impaired relaxation.
43. 43 Oberst L, Zhao G, Park JT, Brugada R, Michael LH, Entmann ML, et al.: Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest 1998, 102:1498-1505.
44. 44 Frey N, Degenhardt M, Lorenzen H-P, Katus HA, Franz WM: Transgenic rats overexpressing a human cardiac troponin T deletion exhibit diastolic dysfunction in the "working heart model." Circulation 1998, 100:1-626.
45. 45 Frey N, Franz WM, Degenhardt M, Lorenzen H-P, Katus HA: Transgenic rats overexpressing wild-type human troponin T show improved contractile performance in the "working heart." Circulation 1999, 100:1-762.
46. 46 Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J: A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest 1998, 102:1292-1300.
47. 47 Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J: In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res 1999, 85:841-847. This report describes a mouse model expressing MyBP-C lacking the myosin-binding domain. Hearts of these mice showed only modest levels of mutant protein. Despite normal levels of wild-type MyBP-C, hearts showed mild hypertrophy, histopathologic changes, and animals had impaired exercise tolerance.
48. 48 McConnell BK, Jones KA, Fatkin D, Arroyo LH, Lee RT, Aristizabal O, et al.: Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999, 104:1235-1244. This description of a mouse model mimicking a human MyBP-C mutation causing FHC showed that homozygous mice develop histopathologic features of FHC but develop progressive ventricular dilation.
49. 49 Muthuchamy M, Pieples K, Rethinasamy P, Hoit B, Grupp IL, Boivin GP, et al.: Mouse model of a familial hypertrophic cardiomyopathy mutation in α-tropomyosin manifests cardiac dysfunction. Circ Res 1999, 85:47-56. The mouse model with α-TM-D175N mutation described here showed typical FHC histopathology. In vivo physiologic analyses showed severe impairment of both contractility and relaxation.
50. 50 Blanchard E, Iizuka K, Christe M, Conner D, Geisterfer-Lowrance A, Schoen F, et al.: Targeted ablation of the murine α-tropomyosin gene. Circ Res 1997, 81:1005-1010.
51. 51 Rethinasamy OP, Muthachamy M, Hewett T, Boivin G, Wolska B, Evans C, et al.: Molecular and physiological effects of α-tropomyosin ablation in the mouse. Circ Res 1998, 82:116-123.
52. 52 Wernicke D, Thiel C, Isac C, Plehm R, Hammes A, Ganten U, et al.: Characterization of a transgenic rat model of familial hypertrophic cardiomyopathy with missense mutations Asp175Asn or Glu180Gly in α-tropomyosin. Circulation 1999, 100:1-268.
53. 53 Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, et al.: Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997, 94:13873-13878.
54. 54 Kittleson MD, Meurs KM, Munro MJ, Kittleson JA, Liu S-K, Pion PD, Towbin JA: Familial hypertrophic cardiomyopathy in Maine Coon cats - An animal model of human disease. Circulation 1999, 99:3172-3180. In this article, a naturally occurring form of FHC in cats is described. This strain of cats showed all the important features of human FHC, including sudden cardiac death.
55. 55 Jackson T, Allard MF, Sreenan CM, Doss LK, Bishop SP, Swain JL: Transgenic animals as a tool for studying the effect of the c-myc proto-oncogene on cardiac development. Mol Cell Biochem 1991, 104:15-19.
56. 56 Hunter JJ, Tanaka N, Rockman HA, Ross Jr J, Chien KR: Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1996, 270:23173-23178.
57. 57 Gruver CL, DeMayo F, Goldstein MA, Means AR: Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology 1993, 133:376-388.
58. 58 Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, et al.: Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 1998, 83:594-601.
59. 59 Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al.: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
60. 60 Sussmann MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, et al.: Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693.
61. 61 Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999, 341:1276-1283. This comprehensive review describes the signaling pathways that are involved in cardiac hypertrophy, some of which may be operational in the pathogenesis of FHC.
62. 62 Marian AJ: Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000, 355:58-60. This article hypothesizes a model for the pathogenesis of FHC and describes the experimental approach to be used.
63. 63 Li RK, Li G, Mickle DA, Weisel RD, Merante F, Luss H, et al.: Overexpression of transforming growth factor-β1 and insulin-like growth factor-1 in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997, 96:874-881.
64. 64 Hasegawa K, Fujiwara H, Koshiji M, Inada T, Ohtani S, Doyama K, et al.: Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996, 27:259-264.
65. 65 Grohas C, Kahlert S, Loebbert K, Stimpel M, Karas RH, Vetter H, Neyses L: Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997, 416:107-112.
66. 66 Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, et al.: Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999, 34:264-273.
67. 67 Janse MJ, Opthof T, Kleber AG: Animal models of cardiac arrhythmias. Cardiovasc Res 1998, 39:165-177.